Молимо вас користите овај идентификатор за цитирање или овај линк до ове ставке:
https://open.uns.ac.rs/handle/123456789/423
Назив: | Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or Prasugrel | Аутори: | Raposeiras-Roubín S. Abu-Assi E. D'Ascenzo F. Fernández-Barbeira S. Kinnaird T. Ariza-Solé A. Manzano-Fernández S. Templin C. Lazar Velicki Xanthopoulou I. Cerrato E. Quadri G. Rognoni A. Boccuzzi G. Montabone A. Taha S. Durante A. Gili S. Magnani G. Autelli M. Grosso A. Flores Blanco P. Garay A. Varbella F. Tommassini F. Caneiro Queija B. Cobas Paz R. Cespón Fernández M. Muñoz Pousa I. Gallo D. Morbiducci U. Domínguez-Rodríguez A. Baz-Alonso J. Valdés M. Cequier Á. Gaita F. Alexopoulos D. Íñiguez-Romo A. |
Кључне речи: | Ticagrelor;Prasugrel;Stent thrombosis;Acute coronary syndrome | Датум издавања: | 1-апр-2019 | Часопис: | Revista Espanola de Cardiologia | Сажетак: | © 2018 Sociedad Española de Cardiología Introduction and objectives: There is little evidence on rates of stent thrombosis (ST) in patients receiving dual antiplatelet therapy (DAPT) with ticagrelor or prasugrel. The aim of this study was to analyze the incidence and predictors of ST after an acute coronary syndrome among patients receiving DAPT with ticagrelor vs prasugrel. Methods: We used data from the RENAMI registry (REgistry of New Antiplatelet therapy in patients with acute Myocardial Infarction), analyzing a total of 4123 acute coronary syndrome patients discharged with DAPT with ticagrelor or prasugrel in 11 centers in 6 European countries. The endpoint was definite ST within the first year. A competitive risk analysis was carried out using a Fine and Gray regression model, with death being the competitive event. Results: A total of 2604 patients received DAPT with ticagrelor and 1519 with prasugrel; ST occurred in 41 patients (1.10%), with a similar cumulative incidence between ticagrelor (1.21%) and prasugrel (0.90%). The independent predictors of ST were age (sHR, 1.03; 95%CI, 1.01-1.06), ST segment elevation (sHR, 2.24; 95%CI, 1.22-4.14), previous myocardial infarction (sHR, 2.56; 95%CI, 1.19-5.49), and serum creatinine (sHR, 1.29; 95%CI, 1.08-1.54). Conclusions: Stent thrombosis is infrequent in patients receiving DAPT with ticagrelor or prasugrel. The variables associated with an increased risk of ST were advanced age, ST segment elevation, previous myocardial infarction, and serum creatinine. Full English text available from: www.revespcardiol.org/en | URI: | https://open.uns.ac.rs/handle/123456789/423 | ISSN: | 3008932 | DOI: | 10.1016/j.recesp.2018.02.024 |
Налази се у колекцијама: | MDF Publikacije/Publications |
Приказати целокупан запис ставки
SCOPUSTM
Навођења
6
проверено 10.05.2024.
Преглед/и станица
28
Протекла недеља
7
7
Протекли месец
0
0
проверено 10.05.2024.
Google ScholarTM
Проверите
Алт метрика
Ставке на DSpace-у су заштићене ауторским правима, са свим правима задржаним, осим ако није другачије назначено.